CTLA4 and urinary bladder carcinoma: Based on the results of this study, the further analysis combined with the TCIA database revealed that the negative rate of PD-1 inhibitor or PD-1 combined with CTLA-4 inhibitors was low in a high-risk population of invasive bladder cancer, which provided a theoretical basis for clinical drug selection (Figure 5(c), supplementary table 8).